Editorial team
ioQuanta Research Desk
-
Evidence date ·How can other treatments change the benefits and risks of cancer immunotherapy?
Review or Meta-AnalysisA 2021 review reports longer time before advanced melanoma worsened with two checkpoint drugs but more serious side effects, while lung-cancer pairings gave mixed results.
-
Evidence date ·Why glioma, a hard-to-treat brain tumor, drew interest in cancer-targeting viruses
Review or Meta-AnalysisA 2021 review brings together completed human studies of cancer-targeting viruses for glioma, where the blood-brain barrier and immune suppression complicate treatment.
-
Evidence date ·What stands between a melanoma treatment carrier and its target
Review or Meta-AnalysisA protein coating can hide a carrier’s immune-stimulating cargo, while uneven tumor vessels complicate delivery. The review also weighs mouse and early human evidence.
-
Evidence date ·Why can an immune target coexist with resistance to treatment in ALK-driven lung cancer?
Review or Meta-AnalysisLab studies linked an ALK gene change to an immune marker, but patient studies found few responses to checkpoint drugs and one combination caused serious liver harm.
-
Evidence date ·Could a mutation found in blood explain why one patient’s lung cancer progressed?
Review or Meta-AnalysisOne patient’s lung cancer progressed after eight cycles of immunotherapy. A newly detected STK11 mutation in blood may help explain why.
-
Evidence date ·How can hidden voids change failure in a vacuum-infused composite?
Review or Meta-AnalysisA 2021 review explains how void location can shape failure in vacuum-infused composites and compares models for cracks, layer separation and local structure.
-
Evidence date ·Why did immune treatment plus platinum stand out before surgery for triple-negative breast cancer?
Review or Meta-AnalysisTracked over timeAcross 26 studies, immune treatment plus platinum stood out on response at surgery, with safety considered alongside the result.
-
Evidence date ·Why better tumor response did not settle the treatment trade-off in triple-negative breast cancer
Review or Meta-AnalysisTracked over timeIn triple-negative breast cancer, adding immunotherapy and platinum to chemotherapy was linked to better response and fewer disease events, but more stopped treatment.
-
Evidence date ·Did adding immune therapy improve response at surgery in both PD-L1 groups with triple-negative breast cancer?
Review or Meta-AnalysisTracked over timeAdding immune therapy to chemotherapy before surgery led to more complete responses and better event-free survival, but also more serious side effects.
-
Evidence date ·How metal-catching materials are cleaned for another cycle
Review or Meta-AnalysisA 2021 review describes natural-polymer materials that capture lead and cadmium. Some can be reused after cleaning, but the metal-bearing rinse still needs handling.